AstraZeneca inks $247M deal with generative AI shop Absci to develop antibody drug for cancer
AstraZeneca is joining forces with Absci in a deal worth up to $247 million focused on using AI to conduct large-scale protein analysis to design …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
